STAAR Surgical (STAA) Expected to Announce Earnings on Wednesday

Key Points

• STAAR Surgical is set to report its Q2 2025 earnings on August 6th, with analysts forecasting a loss of $0.56 per share and revenues of $40.93 million.
• The company's stock recently saw a 3.5% decline on the market, with a current trading price of $18.58 and a market capitalization of $920.27 million.
• STAAR Surgical's board has approved a $30 million stock buyback program, signaling management's belief that the shares are undervalued.

STAAR Surgical (NASDAQ:STAA - Get Free Report) is expected to issue its Q2 2025 quarterly earnings data before the market opens on Wednesday, August 6th. Analysts expect the company to announce earnings of ($0.56) per share and revenue of $40.93 million for the quarter.

STAAR Surgical Stock Down 0.9%

STAAR Surgical stock traded down $0.16 during mid-day trading on Friday, hitting $17.76. 726,166 shares of the company's stock traded hands, compared to its average volume of 617,007. The firm has a 50 day moving average price of $17.54 and a 200 day moving average price of $18.31. The company has a market cap of $879.65 million, a PE ratio of -12.33 and a beta of 0.61. STAAR Surgical has a one year low of $13.50 and a one year high of $41.00.

STAAR Surgical announced that its Board of Directors has authorized a stock repurchase plan on Friday, May 16th that allows the company to buyback $30.00 million in outstanding shares. This buyback authorization allows the medical instruments supplier to buy up to 3.2% of its shares through open market purchases. Shares buyback plans are generally a sign that the company's board of directors believes its shares are undervalued.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Goldman Sachs Group Inc. increased its position in STAAR Surgical by 33.4% during the first quarter. Goldman Sachs Group Inc. now owns 544,843 shares of the medical instruments supplier's stock worth $9,606,000 after buying an additional 136,390 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its position in shares of STAAR Surgical by 11.6% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 123,347 shares of the medical instruments supplier's stock valued at $2,175,000 after purchasing an additional 12,841 shares during the last quarter. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its position in shares of STAAR Surgical by 4.5% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 29,390 shares of the medical instruments supplier's stock valued at $518,000 after purchasing an additional 1,267 shares during the last quarter. 96.70% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

A number of analysts have recently commented on STAA shares. Needham & Company LLC reissued a "hold" rating on shares of STAAR Surgical in a research note on Wednesday, May 21st. Canaccord Genuity Group reaffirmed a "hold" rating and set a $20.00 target price on shares of STAAR Surgical in a research report on Tuesday, May 27th. Wells Fargo & Company initiated coverage on STAAR Surgical in a research report on Monday, April 21st. They set an "equal weight" rating and a $17.00 target price on the stock. Mizuho upped their price target on STAAR Surgical from $17.00 to $18.00 and gave the company a "neutral" rating in a research report on Wednesday, July 16th. Finally, Piper Sandler upgraded STAAR Surgical to a "hold" rating in a research note on Wednesday, June 18th. One analyst has rated the stock with a sell rating, nine have given a hold rating and one has given a buy rating to the company. According to MarketBeat, STAAR Surgical currently has an average rating of "Hold" and an average target price of $18.00.

STAAR Surgical Company Profile

STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia.